Hairy Cell Leukemia Clinical Trials
Here are the 5 most popular medical studies for hairy cell leukemia
CAR T-cell Therapy
Brexucabtagene Autoleucel + Fludarabine + Cyclophosphamide for Rare B-cell Malignancies
This trial studies a new gene therapy to treat 4 rare B-cell malignancies, such as Waldenstrom macroglobulinemia, Richter transformation, Burkitt lymphoma, and hairy cell leukemia.
Kinase Inhibitor
Encorafenib + Binimetinib for Hairy Cell Leukemia
This trial is testing whether a combination of two drugs is more effective than one drug at treating hairy cell leukemia that has come back or does not respond to treatment, in people with a BRAF gene mutation. Eligible participants will take the study drugs by mouth in 28-day cycles and have follow-up visits with the research team.
Popular filter options for hairy cell leukemia trials
HCL Clinical Trials
View 19 HCL medical studies.
Kinase Inhibitor
Low Dose Vemurafenib + Rituximab for Hairy Cell Leukemia
This trial is testing a new, oral drug combination for the treatment of hairy cell leukemia that is hoped to be more effective and have fewer side effects than the current standard-of-care chemotherapy.
Monoclonal Antibodies
MGD024 for Hematologic Malignancies
This trial is testing the safety and effectiveness of a new drug, MGD024, for blood cancers that have not responded to standard therapies or have relapsed after treatment. The study will last up to 1 year, and patients will be checked for side effects and response to treatment throughout.
Immunotoxin
Moxetumomab + Rituximab/Ruxience for Hairy Cell Leukemia
This trial is testing the safety of combining two drugs, Rituximab/Ruxience and Moxetumomab pasudotox, to treat hairy cell leukemia or a variant of it. Eligible participants must be 18 or older and the cancer must not have responded to standard therapy.
BRAF Inhibitor
Vemurafenib + Obinutuzumab for Classical Hairy Cell Leukemia
This trial is testing a combination of two drugs, vemurafenib and obinutuzumab, to treat hairy cell leukemia (HCL) that has not been treated before. The trial will have 28 patients total, and will test the efficacy of the combination treatment. If the treatment is successful, bone marrow aspirate and biopsy will be performed to assess response and evaluate minimal residual disease (MRD).
Follicular Lymphoma Clinical Trials
View 6 Follicular Lymphoma medical studies.
Chemotherapy
Lenalidomide + Obinutuzumab + Oral Azacitidine for CD20 Positive B-cell Lymphoma
This trial is testing a new drug, CC-486, to see if it is effective in treating patients with B-cell lymphoma that has come back or has not responded to treatment. The new drug will be tested in combination with lenalidomide and obinutuzumab.
CAR T-cell Therapy
Cellular Immunotherapy + Chemotherapy for Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, and B-Cell Prolymphocytic Leukemia
This trial is studying the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has come back.
Hairy Cell Leukemia Clinical Trials With No Placebo
View 19 hairy cell leukemia medical studies that do not have a placebo group.
Kinase Inhibitor
Low Dose Vemurafenib + Rituximab for Hairy Cell Leukemia
This trial is testing a new, oral drug combination for the treatment of hairy cell leukemia that is hoped to be more effective and have fewer side effects than the current standard-of-care chemotherapy.
Monoclonal Antibodies
MGD024 for Hematologic Malignancies
This trial is testing the safety and effectiveness of a new drug, MGD024, for blood cancers that have not responded to standard therapies or have relapsed after treatment. The study will last up to 1 year, and patients will be checked for side effects and response to treatment throughout.
Immunotoxin
Moxetumomab + Rituximab/Ruxience for Hairy Cell Leukemia
This trial is testing the safety of combining two drugs, Rituximab/Ruxience and Moxetumomab pasudotox, to treat hairy cell leukemia or a variant of it. Eligible participants must be 18 or older and the cancer must not have responded to standard therapy.
BRAF Inhibitor
Vemurafenib + Obinutuzumab for Classical Hairy Cell Leukemia
This trial is testing a combination of two drugs, vemurafenib and obinutuzumab, to treat hairy cell leukemia (HCL) that has not been treated before. The trial will have 28 patients total, and will test the efficacy of the combination treatment. If the treatment is successful, bone marrow aspirate and biopsy will be performed to assess response and evaluate minimal residual disease (MRD).
Frequently Asked Questions
Introduction to hairy cell leukemia
What are the top hospitals conducting hairy cell leukemia research?
When it comes to cutting-edge clinical trials in the battle against hairy cell leukemia, several top-notch hospitals are leading the way. The National Institutes of Health Clinical Center, located in Bethesda, Maryland, is a prominent institution at the forefront of research for this rare form of leukemia. With six active trials and eight completed trials focused on hairy cell leukemia since their first recorded trial in 2008, they represent a hub of innovation and hope for patients.
Joining them in advancing treatment options is Boston's Dana Farber Cancer Institute. Through their dedication and expertise, they have conducted three ongoing clinical trials for hairy cell leukemia while also accomplishing four previous studies since initiating their inaugural trial in 2012.
Notably, another branch of the National Institutes of Health Clinical Center situated at 9000 Rockville Pike in Bethesda has also made significant contributions to combating this disease. With three active clinical trials and six prior investigations into hairy cell leukemia dating back to 2006, their commitment to finding effective treatments cannot be overstated.
Meanwhile, Memorial Sloan Kettering Cancer Center shines as one of New York City's foremost institutions conducting research into hairy cell leukemia. Their two ongoing clinical trials build upon the foundation laid by three previously completed studies since embarking on their maiden investigation in 2009.
Lastly but certainly not least is M D Anderson Cancer Center located within Houston which possesses two current actively pursued trails regarding Hairy Cell Leukemia alongside participation that spans five all-time trail records having begun its very first experiment around nineteen years ago during year-2004
These hospitals serve as beacons of hope for individuals grappling with this rare form of cancer. As these medical centers continue to push boundaries through innovative research initiatives aimed at understanding and eradicating hairy cell leukemia once and for all
Which are the best cities for hairy cell leukemia clinical trials?
When it comes to hairy cell leukemia clinical trials, several cities emerge as prominent hubs for research and development. Bethesda, Maryland leads the way with 9 active trials investigating treatments like Rituximab, Cladribine, and binimetinib. Following closely behind is Boston, Massachusetts with 4 ongoing studies focused on Vemurafenib, MGD024, and Acalabrutinib. Columbus, Ohio also plays a significant role in this field with 3 active trials examining Acalabrutinib, Ibrutinib, and Vemurafenib. Additionally, Houston Texas contributes to the advancement of knowledge with 3 active trials studying Acalabrutinib and Ibrutinib among others. Lastly La Jolla California offers participation in two clinical trials that explore innovative approaches such as low dose vemurafenib plus rituximab. These cities are at the forefront of hairy cell leukemia research providing patients access to cutting-edge treatments that may improve outcomes and quality of life.
Which are the top treatments for hairy cell leukemia being explored in clinical trials?
Hairy cell leukemia, a rare form of blood cancer, is the focus of several promising treatments currently being explored in clinical trials. Leading the pack is vemurafenib, with two active trials and an all-time count of two trials dedicated to hairy cell leukemiad cancer, is the focus of several promising treatments currently being explored in clinical trials. Leading the pack is vemurafenib, with two active trials and an all-time count of two trials dedicated to hairy cell leukemia since its introduction in 2012. Rituximab follows closely behind with two ongoing trials and five total hairy cell leukemia studies since 2004. Another notable contender is low dose vemurafenib plus rituximab, showing promise in one current trial after its listing in 2022. Additionally, MGD024 and binimetinib are also under investigation through their involvement in one active trial each for hairy cell leukemia. These innovative treatments offer hope for improved outcomes against this challenging disease.
What are the most recent clinical trials for hairy cell leukemia?
Exciting advancements have been made in the field of hairy cell leukemia through recent clinical trials. These studies offer new hope and potential treatment options for patients battling this rare form of leukemia. Among these trials is MGD024, a Phase 1 trial that became available on 7/13/2022. Additionally, CD22CART cell infusion has shown promise in early-phase trials as a potential therapy for hairy cell leukemia. Another notable trial investigated the combination of low dose vemurafenib and rituximab, which may provide an effective treatment approach for patients with this condition. The development of binimetinib as a potential therapeutic option is also underway in Phase 2 trials for hairy cell leukemia. It's important to note that although several promising treatments are being explored, further research is needed to fully assess their efficacy and safety profiles.
What hairy cell leukemia clinical trials were recently completed?
Recently completed clinical trials have made significant strides in the treatment of hairy cell leukemia. Notably, a trial sponsored by the National Cancer Institute (NCI) investigated the efficacy of vemurafenib and rituximab combination therapy, with promising results. Additionally, another trial conducted by Memorial Sloan Kettering Cancer Center explored the use of cladribine followed by pembrolizumab as a potential treatment approach. These recent advancements highlight the commitment to advancing therapies for hairy cell leukemial Cancer Institute (NCI) investigated the efficacy of vemurafenib and rituximab combination therapy, with promising results. Additionally, another trial conducted by Memorial Sloan Kettering Cancer Center explored the use of cladribine followed by pembrolizumab as a potential treatment approach. These recent advancements highlight the commitment to advancing therapies for hairy cell leukemia and providing hope for patients facing this rare form of blood cancer.